How has Geisinger reduced device costs in clinically sensitive areas? Attend a webinar, March 7
Skip to Content

Clinical Evidence Doesn’t Support Claims of Superiority

With a price tag 10 to 40 times higher than comparators, US health systems currently spend over $290M per year on Ofirmev. This case study describes how one health system reviewed the evidence to determine that the drug’s clinical benefits did not offset its high cost.

Read this article to:

  • Learn how one organization uncovered¬†$1M+ in savings off a base spend of $2.2M
  • See what the evidence says about Ofirmev’s safety and efficacy¬†compared to other parenteral analgesics
  • Discover how the health system partnered with Lumere to develop a plan for change